fremanezumab approv fda option quarterli dose
teva receiv fda approv key pipelin drug ajovi
fremanezumab migrain prevent fda also approv quarterli
dose drug provid import point differenti rel
competitor amgn/nv drug suppli pre-fil
syring oppos auto-injector competitor high
rate inject site reaction clinic trial compar
aimovig trial result look see physician
adopt ajovi practic howev clearli signific demand
new class cgrp antibodi friday approv provid teva
import potenti growth driver compani work overcom
challeng face copaxon us gener larg debt load
expect strong posit reaction stock increas target
price base ev/ebitda look see teva
commerci import asset come month becom
construct stock long-term outlook ep
estim main
risk teva call better/wors commerci ajovi and/or
execut gener busi current expect
incorpor ajovi model updat increas tp
given manufactur issu surround ajovi
previous assum launch move
also increas peak sale somewhat given inclus
quarterli dose product label beyond ajovi also take
opportun account recent fda approv teva receiv
gener epipen expect launch late year also greater
headwind face near-term due currenc fluctuat
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
teva israel-bas pharmaceut compani focus primarili
research develop commerci gener
specialti drug two oper segment gener medicin
specialti medicin
price sep rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat driven larg part effici
optim gener busi slower anticip
eros copaxon sale launch new product
compani debt situat resolv effici
grey sky valuat driven larg part bearish
assumpt around sale copaxon gener
busi us need renegoti debt
 close
sale
incom invest
incom incom tax
share loss associ compani net
net incom non-control interest
net gain loss attribut non-control interest
dividend prefer share
weight average share use calcul dilut ep
compani mention price
